- €86.19bn
- €103.69bn
- €46.72bn
Early US flu season, current strain may signal risk for younger people; doctors urge shots
Brief: Sanofi Starts Work On Insulin Facility In Germany
RCS - Accession Theraptcs. - Accession Therapeutics: Board appointments
Europe Research Roundup: AJ Bell, CMC Markets, Nestle
French and Benelux stocks-Factors to watch
Brief: Sanofi, pCPA Sign Letter Of Intent For Dupixent® Across Four Indications In Dermatology, Respiratory Care
Sanofi avoids fine as EU accepts offer to stop disparaging rival vaccine (updated)
Sanofi avoids fine as EU accepts offer to stop disparaging rival vaccine
Brief: Regeneron Pharmaceuticals - Sanofi Enter Sixth Amendment To License And Collaboration Agreement
Factbox: Global healthcare companies invest billions to boost US presence
US FDA advisers recommend flu vaccine strains for 2027 Southern Hemisphere season (updated)
US FDA advisers recommend flu vaccine strains for 2027 Southern Hemisphere season
Sanofi’s Regeneron fix requires extra shot of M&A
Sanofi, Regeneron expand tie-up with $8 billion drug-development deal, settle legal dispute (updated)
Sanofi to pay Regeneron $1 billion upfront in expanded immunology deal
Brief: Health Canada Sanofi-Aventis Canada Recalls Insulin Pens & Cartridges Potentially Frozen During Shipping
European drugmakers call for faster trials, more spending to compete with US, China
Sullivan & Cromwell taps Weil's London M&A leader (updated)
Sullivan & Cromwell taps Weil's London M&A leader